HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Toremifene (Fareston)

A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.

Also Known As:

Fareston; FC-1157a; Toremifene Citrate; Toremifene Citrate (1:1); Toremifene, (E)-Isomer; Citrate, Toremifene; FC 1157a; FC1157a; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-

Networked: 369 relevant articles (65 outcomes, 97 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Benzylidene Compounds
        Stilbenes: 79
        Tamoxifen: 10496
        Toremifene: 369
        alpha-sulfoxytoremifene

Experts

1.	Smith, Matthew R: 10 articles (01/2013 - 01/2002)
2.	Sakurai, Kenichi: 7 articles (10/2014 - 06/2004)
3.	Amano, Sadao: 7 articles (10/2014 - 06/2004)
4.	Steiner, Mitchell S: 7 articles (01/2013 - 03/2002)
5.	Enomoto, Katsuhisa: 6 articles (10/2014 - 11/2008)
6.	Takashima, Shigemitsu: 5 articles (05/2014 - 01/2009)
7.	Kimura, Morihiko: 5 articles (05/2014 - 04/2006)
8.	Holli, K: 5 articles (10/2003 - 09/2000)
9.	Taneja, Samir S: 4 articles (08/2013 - 01/2005)
10.	Hancock, Michael L: 4 articles (02/2013 - 10/2010)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/01/2012 - "[A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer]." 08/01/1990 - "The efficacy of high dose toremifene (240 mg daily) in postmenopausal women with advanced breast cancer is investigated in this ongoing study. " 07/01/1999 - "The combination of high-dose toremifene with CAF is potentially effective against ADM-resistant breast cancer." 04/01/1998 - "Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer." 05/01/1997 - "Toremifene, in doses up to 240 mg/d, is an effective, safe treatment for postmenopausal women with ER-positive/unknown advanced breast cancer."
2.	Prostatic Neoplasms (Prostate Cancer) 01/01/2013 - "Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. " 10/01/2010 - "Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. " 09/01/2006 - "Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population." 01/01/2013 - "In this double-blind, placebo controlled phase III study 646 men receiving androgen deprivation therapy for prostate cancer were assigned to toremifene (80 mg by mouth daily) and 638 were assigned to placebo. " 10/01/2010 - "In this double-blind, placebo controlled phase III study 646 men receiving androgen deprivation therapy for prostate cancer were assigned to toremifene (80 mg by mouth daily) and 638 were assigned to placebo. "
3.	Neoplasms (Cancer) 03/01/1998 - "Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small. " 08/01/1990 - "Toremifene (200 micrograms/day) was effective in preventing the development of 7,12-dimethylbenzanthracene-induced rat mammary tumors when given po from day 28 after carcinogen administration. " 11/01/1991 - "Phase I study of toremifene in patients with advanced cancer." 08/01/1990 - "Clinical trials with toremifene should employ an indefinite treatment strategy to control tumor recurrence in adjuvant studies." 08/01/1990 - "Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer."
4.	Prostatic Intraepithelial Neoplasia 02/10/2013 - "We evaluated the efficacy of toremifene citrate 20 mg in PCa prevention among men with isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy. " 06/01/2003 - "Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia." 03/01/2002 - "High-grade prostatic intraepithelial neoplasia was observed in animals in the placebo group, but not in animals treated with toremifene. " 09/01/2006 - "A randomized, double-blind, dose finding, placebo controlled, parallel group clinical study was done to determine the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia treated with toremifene. " 09/01/2006 - "A total of 514 patients with high grade prostatic intraepithelial neoplasia and no evidence of prostate cancer on screening biopsy were randomized to 20, 40 or 60 mg toremifene, or placebo daily for 12 months. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/20/2003 - "[The preliminary results of a phase II randomized clinical trial of high-dose toremifene chemosensitization in stage IIIB/IV non-small cell lung cancer]." 10/20/2003 - "To investigate whether high-dose toremifene can enhance the efficacy of chemotherapy in non small cell lung cancer. " 01/01/1998 - "High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically." 12/01/1996 - "Toremifene at the doses used did not enhance the effect or toxicity of ifosfamide in previously untreated non-small cell lung cancer patients." 12/01/1996 - "Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer."

Related Drugs and Biologics

1.	Tamoxifen
2.	Toremifene (Fareston)
3.	Estrogens (Estrogen)
4.	Selective Estrogen Receptor Modulators (SERM)
5.	Estrogen Receptor Modulators (Antiestrogen)
6.	Hormones
7.	triphenylethylene
8.	Aromatase (CYP19)
9.	Paclitaxel (Taxol)
10.	Gonadotropin-Releasing Hormone (GnRH)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intramuscular Injections
3.	Injections
4.	Immunotherapy
5.	Oral Administration